Publications
282 results found
Andreotti F, Geisler T, Collet J-P, et al., 2023, Acute, periprocedural and longterm antithrombotic therapy in older adults 2022 Update by the ESC Working Group on Thrombosis, EUROPEAN HEART JOURNAL, Vol: 44, Pages: 262-279, ISSN: 0195-668X
- Author Web Link
- Cite
- Citations: 8
Kanji R, Leader J, Memtsas V, et al., 2023, Measuring Thrombus Stability at High Shear, Together With Thrombus Formation and Endogenous Fibrinolysis: First Experience Using the Global Thrombosis Test 3 (GTT-3), CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, Vol: 29, ISSN: 1076-0296
Gorog DA, Gue YX, Chao T-F, et al., 2022, Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society, EUROPACE, Vol: 24, Pages: 1844-1871, ISSN: 1099-5129
- Author Web Link
- Cite
- Citations: 8
Kanji R, Gue YX, Farag MF, et al., 2022, Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction, JACC-BASIC TO TRANSLATIONAL SCIENCE, Vol: 7, Pages: 1069-1082, ISSN: 2452-302X
- Author Web Link
- Cite
- Citations: 4
Memtsas VP, Gue YX, Kanji R, et al., 2022, Diurnal and weekly variation in thrombotic and fibrinolytic status in healthy individuals, EuroThrombosis and EuroVessels Meeting, Publisher: OXFORD UNIV PRESS, ISSN: 0008-6363
Kanji R, Gue YX, Farag MF, et al., 2022, Bi-directional cross talk between coagulation, fibrinolysis and inflammatory pathways in patients with ST-segment elevation myocardial infarction, EuroThrombosis and EuroVessels Meeting, Publisher: OXFORD UNIV PRESS, ISSN: 0008-6363
Kanji R, Panoulas VF, Duncan A, et al., 2022, Increasing transvalvular gradient related to effectiveness of endogenous fibrinolysis in patients with severe aortic stenosis, Publisher: OXFORD UNIV PRESS, ISSN: 0008-6363
Farag M, Jeyalan V, Ferreiro JL, et al., 2022, Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review, FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol: 9, ISSN: 2297-055X
Gue YX, Gorog DA, Lip GYH, 2022, Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?, CIRCULATION, Vol: 146, Pages: 1207-1209, ISSN: 0009-7322
Rao SV, Kirsch B, Bhatt DL, et al., 2022, A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction., Circulation, Vol: 146, Pages: 1196-1206
BACKGROUND: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). METHODS: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition was assessed at 4 weeks. The prespecified main safety outcome was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding comparing all pooled asundexian doses with placebo. The prespecified efficacy outcome was a composite of cardiovascular death, MI, stroke, or stent thrombosis comparing pooled asundexian 20 and 50 mg doses with placebo. RESULTS: The median age was 68 years, 23% of participants were women, 51% had ST-segment-elevation MI, 80% were treated with aspirin plus ticagrelor or prasugrel, and 99% underwent percutaneous coronary intervention before randomization. Asundexian caused dose-related inhibition of FXIa activity, with 50 mg resulting in >90% inhibition. Over a median follow-up of 368 days, the main safety outcome occurred in 30 (7.6%), 32 (8.1%), 42 (10.5%), and 36 (9.0%) patients receiving asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian versus placebo: hazard ratio, 0.98 [90% CI, 0.71-1.35]). The efficacy outcome occurred in 27 (6.8%), 24 (6.0%), 22 (5.5%), and 22 (5.5%) patients assigned asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian 20 and 50 mg versus placebo: hazard ratio, 1.05 [90% CI, 0.69-1.61]). CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to asp
Davidson SM, Lukhna K, Gorog DA, et al., 2022, RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19 (Jun, 10.1007/s10557-021-07221-y, 2021), CARDIOVASCULAR DRUGS AND THERAPY, Vol: 36, Pages: 931-931, ISSN: 0920-3206
Kaski JC, Cubedo J, Lluch N, et al., 2022, ApoJ-Glyc, an early marker of myocardial ischaemia, rapidly maps improved myocardial perfusion in STEMI patients undergoing successful primary PCI, Publisher: OXFORD UNIV PRESS, Pages: 1356-1356, ISSN: 0195-668X
Davidson SM, Lukhna K, Gorog DA, et al., 2022, RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19, CARDIOVASCULAR DRUGS AND THERAPY, Vol: 36, Pages: 925-930, ISSN: 0920-3206
- Author Web Link
- Cite
- Citations: 4
Gorog DA, Gue YX, Chao T-F, et al., 2022, Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper, THROMBOSIS AND HAEMOSTASIS, Vol: 122, Pages: 1625-1652, ISSN: 0340-6245
- Author Web Link
- Cite
- Citations: 14
Lyon AR, Lopez-Fernandez T, Couch LS, et al., 2022, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC), EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, Vol: 23, Pages: E333-E465, ISSN: 2047-2404
- Author Web Link
- Cite
- Citations: 23
Gorog DA, Massberg S, 2022, Neutrophil Extracellular Traps in the Infarct-Related Coronary Artery-A Marker or Mediator of Adverse Outcome?, THROMBOSIS AND HAEMOSTASIS, Vol: 122, Pages: 1251-1254, ISSN: 0340-6245
- Author Web Link
- Cite
- Citations: 1
Gue YX, Gorog DA, Lip GYH, 2022, Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease Does Less Mean More?, JAMA CARDIOLOGY, Vol: 7, Pages: 794-795, ISSN: 2380-6583
RECOVERY Collaborative Group, 2022, Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis., The Lancet, Vol: 400, Pages: 359-368, ISSN: 0140-6736
BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was done, which included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) and is ongoing. FINDINGS: Between Feb 2 and Dec 29, 2021, from 10 852 enrolled, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% were receiving tocilizumab (with planned use within the next 24 h recorded for a further 9%). Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77-0·99; p=0·028). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of eight previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths), in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0·57; 95% CI 0·45-0·72). Including the results from RECOVERY in an updated meta-analysis of all nine completed t
Gorog DA, Storey RF, Gurbel PA, et al., 2022, Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium, NATURE REVIEWS CARDIOLOGY, Vol: 19, Pages: 475-495, ISSN: 1759-5002
- Author Web Link
- Cite
- Citations: 114
Kanji R, Gue YX, Saw AM, et al., 2022, Does targeted temperature management increase the risk of stent thrombosis in survivors of out-of-hospital cardiac arrest? A single centre experience, 6th Congress of the ESC-Council on Basic Cardiovascular Science, Publisher: OXFORD UNIV PRESS, ISSN: 0008-6363
Lip GYH, Kotalczyk A, Teutsch C, et al., 2022, Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry, CLINICAL RESEARCH IN CARDIOLOGY, Vol: 111, Pages: 560-573, ISSN: 1861-0684
- Author Web Link
- Cite
- Citations: 6
Vandenbriele C, Arachchillage DJ, Frederiks P, et al., 2022, Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock, Journal of the American College of Cardiology, Vol: 79, Pages: 1949-1962, ISSN: 0735-1097
Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), requires meticulous postimplantation management. Because systemic anticoagulation is needed to prevent pump thrombosis, patients are exposed to increased bleeding risk, further aggravated by sepsis, thrombocytopenia, and high shear stress–induced acquired von Willebrand syndrome. The precarious balance between bleeding and thrombosis in percutaneous VAD–supported cardiogenic shock patients is often the main reason that patient outcomes are jeopardized, and there is a lack of data addressing optimal anticoagulation management strategies during percutaneous VAD support. Here, we present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discuss pitfalls of heparin monitoring in critically ill patients. This review will guide physicians toward a more standardized (anti)coagulation approach to tackle device-related morbidity and mortality in this critically ill patient group.
Lip GYH, Kotalczyk A, Teutsch C, et al., 2022, Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (Mar, 10.1007/s00392-022-01996-2, 2022), CLINICAL RESEARCH IN CARDIOLOGY, Vol: 111, Pages: 593-593, ISSN: 1861-0684
Piccini JP, Caso V, Connolly SJ, et al., 2022, Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study, LANCET, Vol: 399, Pages: 1383-1390, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 70
Kanji R, Vandenbriele C, Arachchillage DRJ, et al., 2022, Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation, THROMBOSIS AND HAEMOSTASIS, Vol: 122, Pages: 480-491, ISSN: 0340-6245
- Author Web Link
- Cite
- Citations: 5
Niezgoda P, Baranska M, Adamski P, et al., 2022, Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study, CARDIOLOGY JOURNAL, Vol: 29, Pages: 324-328, ISSN: 1897-5593
- Author Web Link
- Cite
- Citations: 3
RECOVERY Collaborative Group, 2022, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet, Vol: 399, Pages: 665-676, ISSN: 0140-6736
BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. METHODS: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (2
RECOVERY Collaborative Group, 2022, Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet, Vol: 399, Pages: 143-151, ISSN: 0140-6736
BACKGROUND: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28 day mortality. All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 22 560 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin. 7351 patients were randomly allocated (1:1) to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0·96, 95% CI 0·89-1·04; p=0·35). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 days, IQR 5 to >28, vs 9 days, IQR 5 to >28) and a higher proportion were discharged from hospital alive within 28 days (75% vs 74%; rate ratio 1·06, 95% CI 1·02-1·10; p=0·0062). Among patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (2
Kubica J, Adamski P, Gorog DA, et al., 2022, Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial, CARDIOLOGY JOURNAL, Vol: 29, Pages: 148-153, ISSN: 1897-5593
- Author Web Link
- Cite
- Citations: 4
Naik R, Mandal I, Gorog DA, 2022, Scoring Systems to Predict Survival or Neurological Recovery after Out-of-hospital Cardiac Arrest, EUROPEAN CARDIOLOGY REVIEW, Vol: 17, Pages: 1-6, ISSN: 1758-3756
- Author Web Link
- Cite
- Citations: 1
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.